We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has iRadimed (IRMD - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
iRadimed is a member of the Medical sector. This group includes 1161 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. iRadimed is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for IRMD's full-year earnings has moved 16.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that IRMD has returned about 5.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 9.9%. This means that iRadimed is performing better than its sector in terms of year-to-date returns.
AllScripts Healthcare (MDRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 13%.
The consensus estimate for AllScripts Healthcare's current year EPS has increased 20.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, iRadimed belongs to the Medical - Instruments industry, which includes 102 individual stocks and currently sits at #171 in the Zacks Industry Rank. Stocks in this group have lost about 17.1% so far this year, so IRMD is performing better this group in terms of year-to-date returns.
In contrast, AllScripts Healthcare falls under the Medical Info Systems industry. Currently, this industry has 47 stocks and is ranked #142. Since the beginning of the year, the industry has moved -15.4%.
Investors interested in the Medical sector may want to keep a close eye on iRadimed and AllScripts Healthcare as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is iRadimed (IRMD) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has iRadimed (IRMD - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
iRadimed is a member of the Medical sector. This group includes 1161 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. iRadimed is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for IRMD's full-year earnings has moved 16.2% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that IRMD has returned about 5.8% since the start of the calendar year. At the same time, Medical stocks have lost an average of 9.9%. This means that iRadimed is performing better than its sector in terms of year-to-date returns.
AllScripts Healthcare (MDRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 13%.
The consensus estimate for AllScripts Healthcare's current year EPS has increased 20.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, iRadimed belongs to the Medical - Instruments industry, which includes 102 individual stocks and currently sits at #171 in the Zacks Industry Rank. Stocks in this group have lost about 17.1% so far this year, so IRMD is performing better this group in terms of year-to-date returns.
In contrast, AllScripts Healthcare falls under the Medical Info Systems industry. Currently, this industry has 47 stocks and is ranked #142. Since the beginning of the year, the industry has moved -15.4%.
Investors interested in the Medical sector may want to keep a close eye on iRadimed and AllScripts Healthcare as they attempt to continue their solid performance.